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Purpose: Multiple genetic factors are associated with chronic obstructive pulmo-
nary disease (COPD). The association of gene encoding vitamin D binding protein 
(VDBP, GC) with COPD has been controversial. We sought to investigate the 
types of GC variants in the Korean population and determine the association of 
GC variants with COPD and lung function in the Korean population. Materials 
and Methods: The study cohort consisted of 203 COPD patients and 157 control 
subjects. GC variants were genotyped by the restriction fragment-length polymor-
phism method. Repeated measures of lung function data were analyzed using a 
linear mixed model including sex, age, height, and pack-years of smoking to in-
vestigate the association of GC genetic factors and lung function. Results: GC1F 
variant was most frequently observed in COPD (46.1%) and controls (42.0%). 
GC1S variant (29.0% vs. 21.4%; p=0.020) and genotype 1S-1S (8.3% vs. 3.4%; 
p=0.047) were more commonly detected in control than COPD. According to lin-
ear mixed model analysis including controls and COPD, subjects with genotype 
1S-1S had 0.427 L higher forced expiratory volume in 1 second (FEV1) than those 
with other genotypes (p=0.029). However, interaction between the genotype and 
smoking pack-year was found to be particularly significant among subjects with 
genotype 1S-1S; FEV1 decreased by 0.014 L per smoking pack-year (p=0.001). 
Conclusion: This study suggested that GC polymorphism might be associated 
with lung function and risk of COPD in Korean population. GC1S variant and 
genotype 1S-1S were more frequently observed in control than in COPD. More-
over, GC1S variant was more common in non-decliners than in rapid decliners 
among COPD.
Key Words:   Vitamin D binding protein, polymorphism, lung function, chronic 
obstructive pulmonary disease
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examined the correlation between GC variants and lung 
function in COPD patients.
MATERIALS AND METHODS
Subjects
The COPD group consisting of 203 patients who were tak-
en from the Korean Obstructive Lung Disease (KOLD) 
Cohort, in which patients with COPD or asthma have been 
enrolled from pulmonary clinics in 17 hospitals in South 
Korea from June 2005 to 2011, were selected for this study. 
The subjects were culled from a KOLD Cohort that ful-
filled the following criteria: post-bronchodilator ratio of 
forced expiratory volume in 1 second (FEV1) to forced vital 
capacity (FEV1/FVC) <0.7, over 40 years of age, smoking 
history of 10 or more pack-years, and no or minimal abnor-
mality on chest radiography. The control group was select-
ed from a community-based prospective cohort, South Ko-
rea. Among 2534 people recruited in 2006, 157 participants 
had a normal pulmonary function test, 10 or more pack-years 
of smoking history, and were over the age of 40. The study 
protocol was approved by the Institutional Review Boards of 
the 17 hospitals included in the KOLD Cohort and the com-
munity-based prospective cohort for control group, and in-
formed written consent was obtained from all patients.
Pulmonary function testing
Spirometry was performed according to American Thoracic 
Society/European Respiratory Society guidelines. Airway 
obstruction is defined by Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) criteria as FEV1/FVC ratio 
of <0.7. The severity of the disease was based on the per-
cent predicted FEV1 in accordance with GOLD criteria.28 
For COPD patients, pulmonary function tests (PFTs) were 
performed at follow-up visits annually and PFT was per-
formed at least two times in 178 (87.6%) with an average 
of 3.7 times during the study. 
Genotyping
For genotyping GC, DNA was extracted from blood and 
polymerase chain reaction (PCR) was performed followed 
by restriction fragment-length polymorphism analysis. The 
region that includes the two point mutation sites in exon 11 
(Glu/Asp 416 and Thr/Lys 420) was amplified.27 We used 
upstream primer of 5ʼTAATGAGCAAATGAAAGAAG3ʼ 
and downstream primer of 5ʼTGAGTAGATTGGAG- 
INTRODUCTION
The most critical risk factor for the development of chronic 
obstructive pulmonary disease (COPD) is cigarette smok-
ing.1 However, only 10--20% of heavy smokers develop air-
way obstruction and --20--30% of COPD patients never 
smoke.2-6 Moreover, previous reports of familial aggregation 
of COPD suggest that genetic components are likely associ-
ated with susceptibility to the development of COPD.7,8
Numerous candidate genes have been reported to be as-
sociated with COPD. These genes are generally related to 
protease-antiprotease interaction, antioxidant effects, xeno-
biotic metabolism, and inflammation and immune response 
pathways.9 One of the candidates involved in inflammation 
and immune reaction is the gene encoding vitamin D bind-
ing protein (VDBP, GC).
VDBP was first described by Hirschfeld in 1959 as a mark-
er in gamma-globulin of human serum and characterized as a 
group-specific component.10 In 1975, it was identified as the 
plasma protein that binds vitamin D.11 The major role of 
VDBP is transporting 25-hydroxyvitamin D, the major cir-
culating form of vitamin D, and 1,25-dihydroxyvitamin D, 
the most active vitamin D metabolite. However, when ex-
pressed by neutrophils, VDBP activates macrophages and 
augments monocyte and neutrophil chemotaxis.12-15 These 
roles of VDBP may contribute to the chronic inflammatory 
response in COPD.
GC, located on chromosome 4, is approximately 42 kb in 
size and has more than 120 reported variants.16 Most of the 
variants are rare except three commonly recognized vari-
ants according to single nucleotide polymorphisms at rs4588 
and rs7041 in exon 11: GC1F (A/G), GC1S (A/T), and GC2 
(C/G).17 The association of these VDBP polymorphisms 
and the risk for COPD has been debated in the literature for 
some time.9,18-26 GC2 tended to be protective variants for 
COPD in Caucasian populations and GC1F tended to be 
risk variants for COPD in Asian populations.27 However, 
Asian studies were conducted in the limited ethnicities, and 
GC variants were not evaluated in South Korea. Moreover, 
the studies were conducted in a small number of patients 
and the relationship with lung function decline was rarely 
investigated.20
The purpose of this study was to evaluate the frequencies 
of GC variants in Koreans with COPD as well as healthy 
subjects. We determined that certain GC variants are associ-
ated with a genetic susceptibility to COPD in Koreans and 
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at the 0.05 significance level was conducted with the linear 
mixed model to consider correlation between repeated mea-
sures. COPD patients and control subjects were included 
for linear mixed model and COPD indicator was included 
as dummy variable to explain their mean differences. We 
also found the heteroscedasticity between COPD patients 
and control subjects, and a different variance-covariance ma-
trix was applied. The optimal correlation structure between 
repeated observations was selected with the likelihood ratio 
test based on the restricted maximum likelihood method and 
the unstructured correlation format was chosen.29,30 Age, sex, 
height, pack-year, and their interactions were included as co-
variates and the significant interactions were selected with 
likelihood ratio test based on the maximum likelihood 
method. Marginal effects are all included in our final mod-
el. In all analyses, a p-value <0.05 was deemed to be statis-
tically significant.
 
RESULTS
 
Population characteristics
All baseline characteristics of the study population are sum-
marized in Table 1. Both groups exhibited a similar gender 
distribution of significant male dominance. COPD patients 
were also of more advanced age than the control popula-
tion. The number of current smokers was higher in controls 
compared to COPD group, whereas former smokers were 
more prevalent in the COPD group than controls. Among 
COPD patients, 17 (8.4%), 101 (49.8%), 73 (36.0%), and 
12 (5.9%) patients were classified as GOLD class I, II, III 
and IV.
Genotyping
The frequency of each variant and genotype in COPD and 
control groups are compared in Table 2. Each of the investi-
gated single nucleotide polymorphisms (rs4588 and rs7041) 
was in HWE in the controls (all p>0.05). Frequencies of 
GC1F, GC1S, and GC2 variants in COPD patients were 
46.1%, 21.4%, and 32.5%, respectively, and 42.0%, 29.0%, 
and 29.0%, in controls, respectively. GC1S variant was 
more frequent in controls than COPD patients (29.0% vs. 
21.4%; p=0.020). There were no significant differences in 
sex ratio, age, and smoking history between the different 
types of genotypes. Genotype 1F-2 was most common in 
both groups and genotype 1S-1S was significantly more 
frequent in control than COPD (8.3% vs. 3.4%; p=0.047).
TGCATAC3ʼ.20,25 The final PCR product was a fragment of 
462 base pairs (bp).
PCR was performed in a thermal cycler (DNA Thermal 
Cycler; Perkin Elmer Cetus; Norwalk, CT, USA). PCR re-
actions were carried out in a volume of 40 μL containing 
100 ng DNA, 1.5 mM MgCl2, 10 mM Tris Cl (pH 8.3), 40 
mM KCl, 4% dimethyl sulphoxide, 0.2 mL of each dNTP 
(Amersham Biosciences KK; Tokyo, Japan), 0.5 μmol/L of 
each primers, and 3.75 units of Taq DNA polymerase (Bi-
oneer, Daejeon, Korea). After amplification, PCR products 
were digested with Hae III (Toyobo; Osaka, Japan), or Eco 
T14 I (Takara Bio; Otsu, Japan) at 37°C overnight. Hae III 
cuts the GC1S product into two bands of 295 bp and 167 
bp, whereas Eco T14 I cuts the GC2 product into two bands 
of 302 bp and 156 bp. GC1F PCR product remains uncut 
by either enzyme (Fig. 1).
Definitions
Rapid decliners were defined as those with a decrease in 
FEV1 ≥3.0% predicted/yr and non-decliners as those with 
an increase in FEV1 ≥0% predicted/yr.24
Data analysis
Differences in distribution and frequency of variants and 
genotypes among the groups were examined by chi-squared 
test. Normally distributed variables are presented as means 
±standard deviations, and non-normally distributed vari-
ables are presented as medians (interquartile range). Geno-
type frequencies and Hardy-Weinberg equilibrium (HWE) 
for the GC between COPD and control groups were deter-
mined by chi-squared test. Statistical inference of the geno-
type effect on FEV1 was conducted with the linear mixed 
model to consider correlation between annually measured 
FEV1. Statistical inference of the genotype effect on FEV1 
Fig. 1. Restriction fragment-length polymorphism analysis of GC. Eco T14 I 
cuts GC2 into two bands of 302 base pairs (bp) and 156 bp, whereas Hae III 
cuts GC1S into two bands of 295 bp and 167 bp. GC1F remains uncut by ei-
ther of the enzymes (E: digested by Eco T14 I, H: digested by Hae III).
100 bp
500 bp
M   E   H   E   H   E   H   E   H   E   H   E   H
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FEV1=0.488-0.013×age (year)+0.027×height (cm)-0.012× 
smoking pack-years-1.711 (for COPD group with genotype 
1S-1S); FEV1=0.488-0.013×age (year)+0.027×height (cm) 
+0.002×smoking pack-years-2.649 (for COPD group with-
out genotype 1S-1S).
DISCUSSION
The potential association of polymorphisms in GC with the 
risk of COPD and lung function was investigated for the 
first time in a Korean population. Subjects with GC1S vari-
ant and genotype 1S-1S were more commonly observed in 
control than in COPD. Moreover, GC1S variant was more 
frequent in non-decliners than in rapid decliners among 
COPD. According to the linear mixed model analysis, gen-
Comparison between rapid decliners and non-decliners
Table 3 shows the comparison of characteristics and geno-
types between 62 rapid decliners and 74 non-decliners. 
Baseline characteristics including sex ratio, age, and spirom-
etry data were not different between the two groups. In com-
paring the variants and genotypes, GC1S variant was more 
frequently observed in non-decliners (26.4% vs. 16.1%, 
p=0.042) and genotype 1F-2 was more frequently observed 
in rapid decliners (37.1% vs. 21.6%, p=0.047).
Parameters associated with FEV1 according to linear 
mixed model analysis
The difference in FEV1 between different genotypes was in-
vestigated by linear mixed model analysis including sex, age, 
height, and pack-years of smoking as shown in Table 4. 
FEV1 was 2.649 L lower in COPD compared to controls 
(p<0.001), 0.345 L lower in females than in males (p=0.014), 
and 0.033 L lower per year of age (p<0.001). Moreover, as 
stature increased by 1 cm, FEV1 also increased by 0.027 L 
(p<0.001). Among the different genotypes, subjects with 
genotype 1S-1S had 0.427 L higher FEV1 than those with 
other genotypes (p=0.029). The genotype/smoking pack-
year interaction was found to be particularly significant 
among subjects with genotype 1S-1S; FEV1 decreased by 
0.014 L per smoking pack-year (p=0.001).
According to the linear mixed model analysis, the final 
equations were obtained as follows: FEV1=0.488-0.033× 
age (year)+0.027×height (cm)-0.012×smoking pack-years 
+0.427 (for control group with genotype 1S-1S); FEV1= 
0.488-0.033×age (year)+0.027×height (cm)+0.002×smok-
ing pack-years (for control group without genotype 1S-1S); 
Table 1. Baseline Characteristics of the Study Population*
Characteristics COPD (n=203) Control (n=157) p value
Sex, male 199 (98.0) 148 (94.3)   0.058
Age, yr      67 (62--71)      53 (47--59) <0.001
Height, cm        165 (162--170)        167 (162--170)    0.571
Smoking status
    Current   55 (27.2)   75 (47.8) <0.001
    Former 147 (72.8)   82 (52.2)
    Pack-yrs 46.0±23.4   30.7±17.4 <0.001
FEV1, L 1.42±0.49   3.17±0.59 <0.001
FEV1, % predicted 53.1±16.9   93.9±12.8 <0.001
FVC, L 2.99±0.81   4.05±0.70 <0.001
FVC, % predicted 79.6±19.3   93.3±11.9 <0.001
FEV1/FVC, % 47.5±10.9 78.3±5.1 <0.001
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
*Data are presented as numbers (percentages) for categorical variables. Continuous variables are presented as means±standard deviations or median 
(interquartile range).
Table 2. Variant and Genotype Frequency of GC in COPD and 
Control Groups*
Variables COPD (n=203) Control (n=157) p value
Variant
    GC1F 187 (46.1) 132 (42.0) 0.281
    GC1S   87 (21.4)   91 (29.0) 0.020
    GC2 132 (32.5)   91 (29.0) 0.309
Genotype
    1F-1F   45 (22.2)   34 (21.7) 0.907
    1F-1S   41 (20.2)   31 (19.7) 0.915
    1F-2   56 (27.6)   33 (21.0) 0.198
    1S-1S   7 (3.4) 13 (8.3) 0.047
    1S-2   32 (15.8)   34 (21.7) 0.199
    2-2   22 (10.8) 12 (7.6) 0.304
COPD, chronic obstructive pulmonary disease.
*Data are presented as numbers (percentages).
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nese population. In another Japanese study, Ito, et al.20 re-
ported a higher frequency of genotype 1F-1F in COPD pa-
tients than in controls (32% vs. 17%, p=0.014). In a Chinese 
population, Lu, et al.23 suggested that GC1F variant and 
genotype 1F-1F were risk factors for COPD (55.8% vs. 
40.4%, p=0.018; 33.3% vs. 11.5%, p=0.005). In a Canadian 
Caucasian population, Horne, et al.18 reported GC2 variant 
and genotype 2-2 were less frequently observed in a COPD 
group. Relative risks of genotype 2-2, 2-1S, 2-1F for COPD 
were 0.8, 0.7, and 0.5, respectively. Moreover, they stated 
that GC1F variant was a significant risk factor for COPD 
(relative risk=4.8). Schellenberg, et al.25 were able to con-
firm that genotype 2-2 was protective against COPD (odds 
ratio=0.17, 95% CI 0.03--0.83). In an American population, 
Kueppers, et al.31 also showed genotype 2-2 as a protective 
factor for COPD (relative risk=0.2). Despite all these re-
ports, several studies have failed to show association be-
tween GC polymorphisms and COPD.24,32
Most of these studies were conducted with a cross-sec-
tional design, such that only the frequencies of certain GC 
polymorphisms were compared between COPD and con-
otype 1S-1S showed higher initial FEV1 than other geno-
types. However, FEV1 decreased more in 1S-1S patients 
than in other genotypes as smoking pack-years increased.
Frequencies of the different genotypes previously dis-
cussed vary based on ethnicity (Table 4). In the Japanese 
population, GC1F variant is most commonly observed, 
comprising approximately half of the population (0.58--
0.61 in COPD and 0.48--0.49 in control). In Caucasians, 
GC1S variant is most common with a frequency of 0.53--
0.61 in COPD and 0.58 in controls.19,20 The Korean popula-
tion in this study showed a similar distribution to the Japa-
nese population.18,25 GC1F variant was most frequent in 
COPD (0.46) and control group (0.42), although its fre-
quency was smaller than that in a Japanese population. 
Prior investigations have demonstrated different results 
regarding the association between polymorphisms in GC 
and risk of COPD; however, studies focusing on Asian pop-
ulations have only been in Chinese and Japanese cohorts. 
Ishii, et al.19 reported GC1F variant and genotype 1F-1F 
were significantly higher in COPD than in control (85.7% 
vs. 75.6%, p=0.036; 36.5% vs. 20.7%, p=0.035) in a Japa-
Table 3. Characteristics of Subjects with COPD Classified by Annual Rates of Decline in FEV1*
Characteristics Rapid decliners (n=62) Non-decliners (n=74) p value
Sex, male 61 (98.4) 73 (98.6) -
Age, yr 65.5 (61--70)    67 (61--70) 0.896
Smoking status
    Current 13 (21.3) 26 (35.1) 0.078
    Former 48 (78.7) 48 (64.9)
    Pack-yrs 44.7±18.1 49.9±28.5 0.197
FEV1, L 1.58±0.49 1.52±0.54 0.482
FEV1, % predicted 61.4±18.7 55.4±17.8 0.058
FVC, L 3.30±0.90 3.08±0.78 0.135
FVC, % predicted 88.2±23.3 80.4±19.3 0.036
FEV1/FVC, % 48.5±10.3 48.9±11.1 0.798
Variant
    GC1F 57 (46.3) 67 (45.3) 0.860
    GC1S 20 (16.1) 39 (26.4) 0.042
    GC2 47 (37.9) 42 (28.4) 0.095
Genotype
    1F-1F 12 (19.4) 16 (21.6) 0.745
    1F-1S 10 (16.1) 19 (25.7) 0.176
    1F-2 23 (37.1) 16 (21.6) 0.047
    1S-1S 2 (3.2) 3 (4.1) -
    1S-2 6 (9.7) 14 (18.9) 0.130
    2-2   9 (14.5) 6 (8.1) 0.235
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
*Data are presented as numbers (percentages) for categorical variables. Continuous variables are presented as means±standard deviations or median 
(interquartile range).
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strated vitamin D deficiency is associated with many types 
of chronic disease and these chronic diseases are all co-
morbidities of COPD. Moreover, vitamin D deficiency is a 
risk factor of lung function decline in COPD through dys-
regulation of adaptive and innate immunity. Janssens, et al.33 
reported that vitamin D deficiency correlates with the se-
verity of COPD and certain types of GC polymorphisms 
are associated with reduced vitamin D levels.34 Moreover, 
VDBP enhances the chemotactic activity of C5-derived 
peptides on human neutrophils and monocytes. Enzymatic 
processing of the carbohydrate side-chain of VDBP trans-
forms the molecule into a potent macrophage-activating 
factor (MAF). In turn, VDBP-MAF stimulates macrophage 
activity. Recently, Wood, et al.35 reported that the GC2 gen-
otype is less efficient at converting VDBP to VDBP-MAF. 
However, there are limitations to the present study. First, 
the sex and age between the two groups were not exactly 
matched. The COPD group was comprised of slightly more 
males and older subjects compared to the control group. 
Though the effect of age was adjusted for by statistical 
trol groups. A few studies demonstrated the relationship of 
GC polymorphisms with lung function decline through lon-
gitudinal analysis.20,24 Although Sandford, et al.24 reported 
no difference between fast decliners and non-decliners, Ito, 
et al.20 showed that GC1F variant still is a risk factor for 
rapid lung function decline even in a longitudinal analysis. 
However, in the latter, the number of subjects with available 
follow-up lung function data was small and the follow-up 
duration of 1 year may not be long enough to accurately ana-
lyze lung function decline. The size of the subjects in our 
study is too small to demonstrate the effect of GC polymor-
phisms on COPD and lung function. However, we have an-
alyzed all the follow-up lung function data of subjects with 
longer duration of follow-up using a linear mixed model. 
There are several possible explanations for the associa-
tion between GC polymorphisms and lung function de-
cline. The major role of VDBP is to bind and transport vita-
min D. Vitamin D is essential for maintaining normal bone 
growth and calcium homeostasis, but it also contributes to 
immune modulation. Epidemiologic research has demon-
Table 4. Frequency of GC Polymorphism and the Risk of Chronic Obstructive Pulmonary Disease in Other Countries
Country Phenotype
No. of cases/
controls
Variant COPD Control
Risk Protective GC1F GC1S GC2 GC1F GC1S GC2
Caucasian
    Canada25 COPD 75/64 - GC2 0.19 0.53 0.28 - - -
    Canada18 COPD 104/413 - GC2 0.19 0.61 0.20 0.12 0.58 0.3
    USA9 COPD
127 families 
  and 304/441
- - - 0.43 0.29 - 0.42 0.27
    USA & 
      Canada24
Rapid decline of FEV1 279/305 - - 0.14 0.55 0.31 0.14 0.57 0.29
    USA & 
      Canada36
High FEV1 vs. Low FEV1
  among COPD
537/533 - - 0.16 0.54 0.30 0.15 0.55 0.30 
    France32
Heavy smoker with high  
  FEV1 vs. never smoker 
  with low FEV1
45/43 - - 0.17 0.60 0.23 0.21 0.46 0.33 
    Iceland22
COPD 112/183 - - 0.09 0.61 0.30 0.10 0.62 0.28
Chronic bronchitis 48/183 GC1F GC2 0.22 0.60 0.18 0.10 0.62 0.28
    Russia21 COPD 298/237 - - 0.49 0.24 0.27 0.48 0.26 0.26
Asian
    Japan20
COPD 103/88 GC1F - 0.58 0.22 0.20 0.49 0.27 0.24
Rapid decline of FEV1 86/21 GC1F - - - - - - -
Emphysema 85 COPD GC1F - - - - - - -
    Japan19
COPD 63/82 GC1F - 0.61 0.18 0.21 0.48 0.27 0.24
DPB 82/82 - - 0.43 0.29 0.28 - - -
    China23 COPD 69/52 GC1F - 0.56 0.24 0.20 0.40 0.29 0.31
    Tartar21 COPD 298/237 GC1F GC2 0.44 0.26 0.30 0.43 0.34 0.23
    Korea 
     (current)
COPD 203/157 -   GC1S 0.46 0.21 0.33 0.42 0.29 0.29
Rapid decline of FEV1 62/74 -   GC1S 0.46 0.16 0.38 0.45 0.26 0.29
COPD, chronic obstructive pulmonary disease; USA, United States of America; FEV1, forced expiratory volume in 1 s; DPB, diffuse panbronchiolitis.
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